<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01166698</url>
  </required_header>
  <id_info>
    <org_study_id>D3020C00001</org_study_id>
    <nct_id>NCT01166698</nct_id>
  </id_info>
  <brief_title>Single Centre, Double-blind, Single and Multiple Ascending Inhaled Doses of AZD9819 in Healthy Subjects</brief_title>
  <official_title>A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group, 2-part Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Inhaled Doses of AZD9819 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess safety and tolerability of AZD9819 following inhaled
      administration of single and multiple increasing doses, and to estimate the maximum dose that
      is tolerated in healthy people.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety variables (ECG variables, adverse events, blood pressure, pulse, body temp, safety lab)</measure>
    <time_frame>Frequent safety measurements during the study from screening period to follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic variables of AZD9819 by assessment of drug concentrations in plasma</measure>
    <time_frame>Multiple PK blood samples from pre-dose until 96 hours post last dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Healthy Volunteers</condition>
  <condition>Safety</condition>
  <condition>Tolerability</condition>
  <arm_group>
    <arm_group_label>AZD9819</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inhaled suspension</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD9819</intervention_name>
    <description>Inhaled single doses of suspension via SPIRA nebuliser</description>
    <arm_group_label>AZD9819</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD9819</intervention_name>
    <description>Inhaled multiple doses of suspension via SPIRA nebuliser, once daily for 10 (maximum 14) days</description>
    <arm_group_label>AZD9819</arm_group_label>
    <other_name>Part B (multiple ascending doses)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inhaled doses of suspension via SPIRA nebuliser given either as single (Part A) or multiple doses (Part B)</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Part A and B</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of signed and dated, written informed consent prior to any study specific
             procedures

          -  Healthy male and female (non-child bearing potential) subjects aged 18 to 50 years
             with suitable veins for cannulation or repeated venepuncture.

          -  Have a body mass index (BMI) between 18 and 30 kg/m2 and weigh at least 50 kg and no
             more than 100 kg

        Exclusion Criteria:

          -  Any clinically significant disease or disorder

          -  Any clinically significant abnormalities at screening examination

          -  Use of any prescribed or non-prescribed medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2010</study_first_submitted>
  <study_first_submitted_qc>July 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2010</study_first_posted>
  <last_update_submitted>November 8, 2011</last_update_submitted>
  <last_update_submitted_qc>November 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 9, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>tolerability</keyword>
  <keyword>healthy</keyword>
  <keyword>inhalation</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

